Rosenfeld S I, Kelly M E, Leddy J P
J Clin Invest. 1976 Jun;57(6):1626-34. doi: 10.1172/JCI108433.
The first recognized human kindred with hereditary deficiency of the fifth component of complement (C5) is described. The proband, a 20-year-old black female with systemic lupus erythematosus since age 11, lacked serum hemolytic complement activity, even during remission. C5 was undetectable in her serum by both immunodiffusion and hemolytic assays. Other complement components were normal during remission of lupus, but C1, C4, C2, and C3 levels fell during exacerbations. A younger half-sister, who had no underlying disease, was also found to lack immunochemically detectable C5. By hemolytic assay, she exhibited 1-2% of the normal serum C5 level and normal concentrations of other complement components. C5 levels of other family members were either normal or approximately half-normal, consistent with autosomal codominant inheritance of the gene determining C5 deficiency. Normal hemolytic titers were restored to both homozygous C5-deficient (C5D) sera by addition of highly purified human C5. In specific C5 titrations, however, it was noted that when limited amounts of C5 were assayed in the presence of low dilutions of either C5D serum, curving rather than linear dose-response plots were consistently obtained, suggesting some inhibitory effect. Further studies suggested that low dilutions of C5D serum contain a factor (or factors) interfering at some step in the hemolytic assay of C5, rather than a true C5 inhibitor or inactivator. Of clinical interest are (a) the documentation of membranous glomerulonephritis, vasculitis, and arthritis in an individual lacking C5 (and its biologic functions), and (b) a remarkable propensity to bacterial infections in the proband, even during periods of low-dose or alternate-day corticosteroid therapy. Other observations indicate that the C5D state is compatible with normal coagulation function and the capacity to mount a neutrophilic leukocytosis during pyogenic infection.
本文描述了首例被确认的遗传性补体第五成分(C5)缺陷的人类家系。先证者是一名20岁的黑人女性,自11岁起患有系统性红斑狼疮,即使在病情缓解期血清中也缺乏溶血补体活性。通过免疫扩散和溶血试验,在其血清中均未检测到C5。狼疮缓解期时其他补体成分正常,但在病情加重时C1、C4、C2和C3水平下降。一名无基础疾病的同父异母妹妹也被发现免疫化学检测不到C5。通过溶血试验,她的血清C5水平仅为正常水平的1%-2%,其他补体成分浓度正常。其他家庭成员的C5水平要么正常,要么约为正常水平的一半,这与决定C5缺陷的基因的常染色体共显性遗传一致。通过添加高度纯化的人C5,纯合C5缺陷(C5D)血清的正常溶血滴度得以恢复。然而,在特定的C5滴定中,注意到当在低稀释度的C5D血清存在下检测有限量的C5时,始终获得的是曲线而非线性剂量反应图,提示存在某种抑制作用。进一步研究表明,低稀释度的C5D血清含有在C5溶血试验的某个步骤产生干扰的一种或多种因子,而非真正的C5抑制剂或灭活剂。具有临床意义的是:(a)在一名缺乏C5(及其生物学功能)的个体中记录到膜性肾小球肾炎、血管炎和关节炎;(b)先证者即使在低剂量或隔日使用皮质类固醇治疗期间也极易发生细菌感染。其他观察结果表明,C5D状态与正常凝血功能以及在化脓性感染期间出现嗜中性白细胞增多的能力是相容的。